Teva Pharmaceuticals Recalls Amikacin Sulfate Injection USP
The company recalls one lot of amikacin sulfate injection USP, 1 gram/4mL (250 mg/mL) vials due to the potential presence of glass particulate in one vial.
Teva Pharmaceuticals announced on March 9, 2016 that it is recalling one lot of amikacin sulfate injection USP, 1 gram/4mL (250 mg/mL), lot number 4750915, because of glass particulate matter found in one vial. Vials of the drug were distributed nationwide through wholesalers, retailers, and pharmacies. As of March 9, the company has not received any adverse event reports.
According to the company, amikacin sulfate injection USP is used as a short-term treatment of Gram-negative bacteria infections and staphylococcal infections as well as an initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease. Amikacin sulfate injection is packaged in pharmacy bulk packages, containing ten 1 gram/4 mL (250 mg/mL) vials per shelf pack.
Teva is asking customers to stop use and quarantine the product. Adverse events may be reported to FDA's MedWatch Adverse Event Reporting program
Source: FDA
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
